Mitchell Capital Management CO Biogen Inc. Transaction History

Mitchell Capital Management CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 02, 2019	SELL	$216.71 - $338.96 $3.07 Million - $4.81 Million	-14,183 Closed	0 $0
Q4 2018 Feb 08, 2019	SELL	$278.5 - $352.75 $187,709 - $237,753	-674 Reduced 4.54%	14,183 $4.27 Million
Q3 2018 Nov 08, 2018	SELL	$293.51 - $383.83 $59,289 - $77,533	-202 Reduced 1.34%	14,857 $5.25 Million
Q2 2018 Aug 10, 2018	SELL	$257.52 - $306.91 $243,613 - $290,336	-946 Reduced 5.91%	15,059 $4.37 Million
Q1 2018 May 04, 2018	SELL	$260.13 - $367.91 $632,376 - $894,389	-2,431 Reduced 13.19%	16,005 $4.38 Million
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $162,741 - $182,282	-529 Reduced 2.79%	18,436 $5.87 Million
Q3 2017 Oct 31, 2017	BUY	$281.15 - $329.69 $5.33 Million - $6.25 Million	18,965	18,965 $5.94 Million

1,049

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $27.2B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Mitchell Capital Management CO, based on Form 13F filings with the SEC.

Stay updated on Mitchell Capital Management CO with notifications on news.